Mustang Bio: What The Latest Development For MB-102 Entails
Mustang Bio is perhaps the most promising subsidiary of Fortress Biotech. Chimeric antigen receptor/T-cell receptor (CAR-T) is a stellar approach to cancer treatment with the superb efficacy and safety.
Mustang is powering differentiated CAR-Ts with key advantages over conventional molecules.
Successful completion of the pre-initial new drug application (“IND”) with the FDA for the lead CAR-T (MB-102). IND for MB-102 is anticipated by Q4 2018.
This idea was discussed in more depth with members of my private investing community, Integrated BioSci Investing.
It is ridiculous the way a lot of people cling to failed ideas. Keynes said, “It’s not bringing in the new ideas that’s so hard. It’s getting rid of the old ones. – Charlie Munger
Mustang Bio (NASDAQ:MBIO) is a highly interesting company that we recently featured through Integrated BioSci Investing (“IBI”). We learned about this company from an IBI member and thereby conducted a deep-dive research to assist our members in their own research due diligence. That being said, Fiscal 2017 sparked the new revolution in the form of a novel method of cancer treatment (CAR-T) with the stellar efficacy and safety (second to none). Despite that Mustang’s CAR-Ts are in their early phase of development, there is key differentiation to confer those drugs with the best chances of clinical success. In this research, we’ll feature an update on the latest development pertaining to MB-102 (a CD-123 CAR-T).